Effect of perindopril on the immune arterial wall remodeling in the rat model of arterial graft rejection

Michel, Jean‐Baptiste; Plissonnier, Didier; Bruneval, Patrick

doi:10.1016/0002-9343(92)90146-3

Cited by 15 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increase in albuminuria was significantly less in patients on ACE inhibitors, providing a rationale for the use of this antihypertensive agent in the graft recipient. This argument is strengthened by experimental observations that clearly document a beneficial effect of ACE inhibitors and angiotensin receptor blockers on intimal proliferation in models of aortic [71,72] and other organ allografts.…”

Section: Antihypertensive Treatment Of the Renal Allograft Recipientmentioning

confidence: 84%

Hypertension after renal transplantation

Schwenger

Zeier

Ritz

2001

Current Science Inc

View full text Add to dashboard Cite

With current immunosuppression, elevated blood pressure is found in almost 90% of renal graft recipients. Major causes of this are impairment of renal function (secondary to chronic allograft nephropathy or less frequently recurrence of primary renal disease), the use of calcineurin inhibitors as immunosuppressants, uncontrolled renin secretion by the shrunken kidneys of the recipient, stenosing lesions of the transplant artery (or the upstream arteries of the recipient), polycythemia, and genetic predisposition to hypertension of the graft donor. Even minor degrees of blood pressure elevation have a significant impact on survival of the recipient and on graft survival, presumably by amplifying vascular injury to the graft. In this respect, elevation of systolic blood pressure and an abnormal circadian blood pressure profile are of particular relevance. In contrast to previous opinion, angiotensin converting enzyme inhibitors are indicated in treatment, but given the causal role of sodium retention and graft vasoconstriction, diuretics and calcium channel blockers remain mainstays of antihypertensive treatment in the renal allograft recipient.

show abstract

Section: Antihypertensive Treatment Of the Renal Allograft Recipientmentioning

confidence: 84%

Hypertension after renal transplantation

Schwenger

Zeier

Ritz

2001

Current Science Inc

View full text Add to dashboard Cite

show abstract

“…Several experimental [[34-36]] and clinical [37] studies have shown that ACE inhibitors are able to inhibit the atherosclerotic process. However, ACE inhibitors have shown little success in preventing restenosis after angioplasty in humans [38], and in the Quinapril Ischemic Event Trial (QUIET) [6] treatment with quinapril after angioplasty failed to reduce mortality and recurrence of angina pectoris in comparison with placebo.…”

Section: Discussionmentioning

confidence: 99%

No effects on myocardial ischaemia in patients with stable ischaemic heart disease after treatment with ramipril for 6 months

Willenheimer

Juul‐Möller

Forslund

et al. 2001

Trials

View full text Add to dashboard Cite

“…In experimental rat aortic allografts, hypertension was associated with a significant increase in intimal thickness involving both smooth muscle cell proliferation and collagen secretion. The angiotensin-converting-enzyme inhibitor perindopril was able to decrease the systolic blood pressure by 30 % and concomitantly reduce intimal thickness by 40 % [67]. It has been observed that antihypertensive drugs decrease the extent of glomerular mesangiolysis and glomerulosclerosis in experimental rat renal transplants [68].…”

Section: Hypertensionmentioning

confidence: 99%

Chronic Allograft Nephropathy (Chronic Allograft Damage): Can It Be Avoided?

Yılmaz

2014

Curr Transpl Rep

View full text Add to dashboard Cite

Although there has been significant progress over the last three decades in renal transplantation, which has been driven primarily by improvements in short-term graft survival, there has been little parallel improvement in long-term outcomes. Advances in histological indicators of chronic allograft pathology have the potential to allow for earlier intervention as well as to provide surrogate endpoints for drug development. Identification of risk factors such as the presence of acute rejection episodes, ischemia/reperfusion injury, donor and recipient age considerations, hypertension, hyperlipidemia, glomerular hyperfiltration, and cytomegalovirus infection will aid in the development of strategies and treatments to mitigate these risks. Of particular importance is the optimization of immunosuppressive regimens to prevent acute rejection episodes. Despite our deeper understanding of clinical risk factors, it is clear that other determinants of graft loss have yet to be identified and that other "missing" factors must play a role in the pathogenesis of late kidney graft loss, highlighting the need for effective therapies to rescue declining graft function.

show abstract

Effect of perindopril on the immune arterial wall remodeling in the rat model of arterial graft rejection

Cited by 15 publications

References 15 publications

Hypertension after renal transplantation

Hypertension after renal transplantation

No effects on myocardial ischaemia in patients with stable ischaemic heart disease after treatment with ramipril for 6 months

Chronic Allograft Nephropathy (Chronic Allograft Damage): Can It Be Avoided?

Contact Info

Product

Resources

About